Translational Psychiatry

期刊简介：Psychiatry has suffered tremendously by the limited translational pipeline. Nobel laureate Julius Axelrod's discovery in 1961 of monoamine reuptake by pre-synaptic neurons still forms the basis of contemporary antidepressant treatment. There is a grievous gap between the explosion of knowledge in neuroscience and conceptually novel treatments for our patients. Translational Psychiatry bridges this gap by fostering and highlighting the pathway from discovery to clinical applications, healthcare and global health. We view translation broadly as the full spectrum of work that marks the pathway from discovery to global health, inclusive. The steps of translation that are within the scope of Translational Psychiatry include (i) fundamental discovery, (ii) bench to bedside, (iii) bedside to clinical applications (clinical trials), (iv) translation to policy and health care guidelines, (v) assessment of health policy and usage, and (vi) global health. All areas of medical research, including — but not restricted to — molecular biology, genetics, pharmacology, imaging and epidemiology are welcome as they contribute to enhance the field of translational psychiatry.

【译文】精神病学因转化渠道有限而遭受巨大损失。诺贝尔奖得主Julius Axelrod于1961年发现的突触前神经元对单胺再摄取至今仍是当代抗抑郁治疗的基础。神经科学知识的爆炸与针对我们患者的新颖治疗方法之间存在巨大的差距。转化精神病学通过培养和突出从发现到临床应用、医疗保健和全球健康的途径来弥合这一差距。我们将转化视为从发现到全球健康（包括在内）的全过程工作。转化精神病学范围内的转化步骤包括（i）基本发现，（ii）从实验室到床边，（iii）从床边到临床应用（临床试验），（iv）转化为政策和医疗保健指南，（v）评估健康政策和使用情况，以及（vi）全球健康。所有医学研究领域，包括但不限于分子生物学、遗传学、药理学、成像和流行病学，都欢迎加入，因为它们有助于增强转化精神病学领域。